These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Hepatitis B surface antigen fusions delivered by DNA vaccination elicit CTL responses to human papillomavirus oncoproteins associated with tumor protection. Haigh O; Kattenbelt J; Cochrane M; Thomson S; Gould A; Tindle R Cancer Gene Ther; 2010 Oct; 17(10):708-20. PubMed ID: 20539319 [TBL] [Abstract][Full Text] [Related]
4. HBsAg-vectored vaccines simultaneously deliver CTL responses to protective epitopes from multiple viral pathogens. Chen D; Edgtton K; Gould A; Guo H; Mather M; Haigh O; Cochrane M; Kattenbelt J; Thomson S; Tindle R Virology; 2010 Mar; 398(1):68-78. PubMed ID: 20006892 [TBL] [Abstract][Full Text] [Related]
5. Endoplasmic reticulum targeting sequence enhances HBV-specific cytotoxic T lymphocytes induced by a CTL epitope-based DNA vaccine. Xu W; Chu Y; Zhang R; Xu H; Wang Y; Xiong S Virology; 2005 Apr; 334(2):255-63. PubMed ID: 15780875 [TBL] [Abstract][Full Text] [Related]
6. A novel HBV DNA vaccine based on T cell epitopes and its potential therapeutic effect in HBV transgenic mice. Li X; Yang X; Jiang Y; Liu J Int Immunol; 2005 Oct; 17(10):1293-302. PubMed ID: 16113237 [TBL] [Abstract][Full Text] [Related]
7. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. Ishioka GY; Fikes J; Hermanson G; Livingston B; Crimi C; Qin M; del Guercio MF; Oseroff C; Dahlberg C; Alexander J; Chesnut RW; Sette A J Immunol; 1999 Apr; 162(7):3915-25. PubMed ID: 10201910 [TBL] [Abstract][Full Text] [Related]
8. [Inducement of cytotoxic T cell responses in mice by constructing a multi-CTL epitope-based DNA vaccine]. Shi L; Yuan YK; Sheng L; Fan GX Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Jul; 22(4):430-2. PubMed ID: 16806000 [TBL] [Abstract][Full Text] [Related]
9. Fusion of HBsAg and prime/boosting augment Th1 and CTL responses to HCV polytope DNA vaccine. Memarnejadian A; Roohvand F Cell Immunol; 2010; 261(2):93-8. PubMed ID: 20056196 [TBL] [Abstract][Full Text] [Related]
10. Single B or T-cell epitope-based DNA vaccine using modified vector induces specific immune response against hepadnavirus. Xu HB; Xu W; Chu YW; Wang Y; Xiong S Immunol Lett; 2005 Jul; 99(2):186-92. PubMed ID: 16009269 [TBL] [Abstract][Full Text] [Related]
11. Silencing an immunodominant epitope of hepatitis B surface antigen reveals an alternative repertoire of CD8 T cell epitopes of this viral antigen. Wieland A; Riedl P; Reimann J; Schirmbeck R Vaccine; 2009 Dec; 28(1):114-9. PubMed ID: 19818719 [TBL] [Abstract][Full Text] [Related]
12. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Daftarian P; Mansour M; Benoit AC; Pohajdak B; Hoskin DW; Brown RG; Kast WM Vaccine; 2006 Jun; 24(24):5235-44. PubMed ID: 16675074 [TBL] [Abstract][Full Text] [Related]
14. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens. Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S Immunol Lett; 2005 Jun; 99(1):85-93. PubMed ID: 15894116 [TBL] [Abstract][Full Text] [Related]
15. A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity. Lin CT; Tsai YC; He L; Calizo R; Chou HH; Chang TC; Soong YK; Hung CF; Lai CH J Biomed Sci; 2006 Jul; 13(4):481-8. PubMed ID: 16649071 [TBL] [Abstract][Full Text] [Related]
16. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545 [TBL] [Abstract][Full Text] [Related]
17. Revealing the potential of DNA-based vaccination: lessons learned from the hepatitis B virus surface antigen. Schirmbeck R; Reimann J Biol Chem; 2001 Apr; 382(4):543-52. PubMed ID: 11405219 [TBL] [Abstract][Full Text] [Related]
18. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer. Riezebos-Brilman A; Walczak M; Regts J; Rots MG; Kamps G; Dontje B; Haisma HY; Wilschut J; Daemen T Gene Ther; 2007 Dec; 14(24):1695-704. PubMed ID: 17928874 [TBL] [Abstract][Full Text] [Related]
19. Enhancing the immunogenicity of exogenous hepatitis B surface antigen-based vaccines for MHC-I-restricted T cells. Schirmbeck R; Reimann J Biol Chem; 1999 Mar; 380(3):285-91. PubMed ID: 10223330 [TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus surface antigen as delivery vector can enhance Chlamydia trachomatis MOMP multi-epitope immune response in mice. Zhu S; Feng Y; Rao P; Xue X; Chen S; Li W; Zhu G; Zhang L Appl Microbiol Biotechnol; 2014 May; 98(9):4107-17. PubMed ID: 24458565 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]